Folks ages 60 and older who had been initially vaccinated with two Pfizer-BioNTech COVID-19 vaccine doses had been higher protected against the omicron coronavirus variant after being boosted with a Moderna vaccine fairly than one other dose of the Pfizer-BioNTech vaccine.
These outcomes are in accordance with interim information from a small however randomized managed medical trial in Singapore and revealed this week within the journal Medical Infectious Illnesses.
The examine—involving 98 wholesome adults—cannot decide if the Moderna booster is solely superior to a Pfizer-BioNTech booster for older adults or if a mix-and-match booster technique is inherently higher. It additionally targeted solely on antibody ranges, which can or might not translate to vital variations in an infection charges and different medical variations. It additionally solely adopted folks for 28 days after a booster, so it is unclear if the Moderna booster’s edge will maintain up over time.
Learn eight remaining paragraphs | Feedback